Perseus Proteomics

Perseus Proteomics FCF Yield

The Free Cash Flow Yield of Perseus Proteomics (4882.T) as of Oct 21, 2026 is -17.72 %. In the previous year, Free Cash Flow Yield was -21.25 % — a change of -16.59% (higher).

FCF Yield

-17.72 %

YoY

-16.59%

Last updated:

Free Cash Flow Yield of Perseus Proteomics is 2026 -17.72 % . Free Cash Flow Yield of Perseus Proteomics was 2025 -21.25 % . It decreases by -16.59% higher compared to the previous year.

The Perseus Proteomics FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2019
-9.22 JPY
Jan 1, 2020
-16.34 JPY
Jan 1, 2021
-11.38 JPY
Jan 1, 2022
-13.66 JPY
Jan 1, 2023
-19.65 JPY
Jan 1, 2024
-26.12 JPY
Jan 1, 2025
-21.25 JPY
Jan 1, 2026
-17.72 JPY
The Perseus Proteomics FCF Yield history
YEARFCF YieldYoY
-17.72 %-16.59%
-21.25 %-18.66%
-26.12 %+32.94%
-19.65 %+43.88%
-13.66 %+19.98%
-11.38 %-30.35%
-16.34 %+77.30%
-9.22 %+159.54%
-3.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Perseus Proteomics Stock analysis

What does Perseus Proteomics do? Perseus Proteomics, Inc. generates revenue through the development and commercialization of antibody-based therapeutics and diagnostics. The company focuses on R&D for cancer treatments, including products like PPMX-T001 targeting glypican 3 (GPC3) on cancer cell membranes, PPMX-T002 targeting cadherin 3 (CDH3), and PPMX-T003 targeting the transferrin receptor (TfR). These therapeutics are developed for commercialization through licensing and manufacturing methods established by the firm. The primary buyers are pharmaceutical companies seeking advanced cancer therapies and diagnostic solutions. The company operates within the biotechnology sector, targeting oncology and related therapeutic markets. Perseus Proteomics, Inc. also engages in antibody research support and the sale of antibodies and reagents, which contribute to its revenue streams. Products such as PPMX-T004, targeting cadherin 3 (CDH3), are part of their portfolio for drug discovery and therapeutic applications. The firm's business model centers on developing proprietary antibody-based solutions for cancer and other diseases, with a focus on licensing and manufacturing partnerships to bring these products to market. Their target segments include pharmaceutical companies and research institutions requiring innovative therapeutic agents and diagnostic tools. The company's revenue is derived from the sale of therapeutic agents and related services, including licensing agreements and manufacturing support. PPMX-T001, PPMX-T002, PPMX-T003, and PPMX-T004 are key products driving commercialization efforts. These products are positioned for use in cancer treatment, with specific targets on cancer cell surface proteins. The firm's business strategy involves establishing manufacturing methods and securing licensing deals to monetize its R&D investments in antibody therapeutics. Perseus Proteomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Perseus Proteomics stock

Free Cash Flow Yield of Perseus Proteomics is -17.72 % in 2026.

Free Cash Flow Yield of Perseus Proteomics changed from -21.25 % to -17.72 %, representing a -16.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Perseus Proteomics since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Perseus Proteomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Perseus Proteomics

All Key Metrics — Perseus Proteomics